Genocea Provides Fourth Quarter 2020 Corporate Update
February 11, 2021 at 07:30 AM EST
GEN-011 and GEN-009 clinical trials continue to advance
ATLASTM stimulatory antigen and inhibitory antigen (InhibigenTM) identification profiled in Cancer Discovery
Announcing SARS-CoV-2 T cell antigen discovery program
Conference call today at 8:30 a.m. E.T.
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2020 and other recent significant developments.
“We are extremely pleased to make progress across multiple fronts by using ATLAS’ unique ability to find the most relevant targets of T cell responses,” said Chip Clark, Genocea President and Chief Executive Officer. “As we advance GEN-009 and GEN-011, our scientific team continues to refine and explore the implications of our pioneering antigen discovery work in multiple disease settings. Included in this is the work we have underway to identify antigens of T cell responses to SARS-CoV-2 (COVID-19), which may prove pivotal to stemming the course of this deadly virus. We are looking forward to continuing this momentum in 2021."
GEN-009 Phase 1/2a clinical trial
SARS-CoV-2 T cell antigen discovery program
Collaboration with the University of Minnesota
Other business updates
Financial and other updates
February investor conferences
About Genocea Biosciences, Inc.
(Tables to follow)
GENOCEA BIOSCIENCES, INC.